SonaCare Medical Congratulates University College London Hospitals NHS Foundation Trust on the Health Service Journal Acute Sector Innovation Award

Share Article

UCLH recognized for their advancements in prostate cancer diagnosis and treatment methods.

"I am tremendously proud of the team who has worked so hard to develop this new approach..." - Dr. Hash Ahmed

SonaCare Medical congratulates the University College London Hospitals NHS Foundation Trust on receiving the 2015 HSJ Acute Sector Innovation Award on November 18th. This prestigious award recognizes annually organizations that cultivate truly innovative methods of improving the patient care experience, and propose exciting enhancements to the medical landscape.

The UCLH team won the award for their innovative approach to the diagnosis and treatment of prostate cancer patients. The changes their innovative pathway of care implemented involves fewer biopsies, a shortened diagnostic period, and the introduction of new treatment options such as focal therapy. The expedited time-frame of the diagnosis, in conjunction with a treatment that is less invasive with an abbreviated hospital stay, provides both reduced costs and risks to the patient.

The leader for the team, Dr. Hash Ahmed, summarizes their impressive accomplishments. "I am tremendously proud of the team who has worked so hard to develop this new approach that prevents unnecessary treatment and provides quicker and more accurate treatment for those patients who need it. We now have 30 per cent fewer biopsies, 30 per cent better cancer detection, fewer radical treatments, a greater number of day-case treatments, and fewer complications and side-effects." Dr. Ahmed also notes that “The work has been made possible by not only working in academic circles, but also by maintaining partnerships with commercial groups, particularly SonaCare Medical, who has supported our efforts in delivering robust and rigorous trials to provide the clinical evidence to drive these changes."

Chief Executive Officer of SonaCare Medical, Dr. Mark Carol, comments that “UCLH has done so much to advance the quality, and reduce the cost, of men's healthcare. This, and the other awards the team has received, is truly deserved. SonaCare Medical is proud to be connected with their innovative efforts and honored that our Sonablate® 500 technology is being used by UCLH to make a difference in patient experience and outcomes.”

About Health Service Journal
Health Service Journal (HSJ) is a weekly news print title and website on the British National Health Service, healthcare management and health policy.

About SonaCare Medical, LLC
SonaCare Medical is a world leader in minimally invasive focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing focused ultrasound related technologies that support precise and innovative procedures for the treatment of a range of medical conditions. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures medical devices, including the following: Sonablate®, which has 510(K) clearance in the U.S. under a De Novo regulatory classification; Sonablate® 500, which has CE Marking and has obtained regulatory authorization in more than 49 countries outside the U.S.; Sonatherm® laparoscopic HIFU surgical ablation system, which has 510(K) clearance in the U.S., has CE Marking and has obtained regulatory authorization in more than 30 countries outside the U.S.

SonaCare Medical, LLC
Erica Griffith (704) 936-1834, EricaGriffith(at)

Forward Looking Statements.
The Company's forward-looking statements are based on management's current expectations and assumptions regarding the Company's business and performance, the economy and other future conditions and forecasts of future events, circumstances and results. As with any projection or forecast, forward-looking statements are inherently susceptible to uncertainty and changes in circumstances. The Company's actual results may vary materially from those expressed or implied in its forward-looking statements. Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or other factors.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Erica Griffith
Follow >
Visit website